Cooper Companies (NASDAQ:COO) Director Maria Rivas Buys 1,000 Shares

The Cooper Companies, Inc. (NASDAQ:COO) Director Maria Rivas purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were purchased at an average price of $82.13 per share, with a total value of $82,130.00. Following the purchase, the director directly owned 11,141 shares in the company, valued at $915,010.33. This trade represents a 9.86% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Cooper Companies Trading Up 0.4%

Shares of Cooper Companies stock opened at $82.75 on Friday. The stock has a market capitalization of $16.22 billion, a P/E ratio of 44.02, a P/E/G ratio of 2.35 and a beta of 1.05. The Cooper Companies, Inc. has a 52-week low of $61.78 and a 52-week high of $100.24. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89. The stock’s 50-day simple moving average is $74.70 and its 200 day simple moving average is $71.99.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the business earned $1.04 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, research analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies declared that its board has approved a stock buyback program on Wednesday, September 17th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical device company to purchase up to 15.4% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Hedge Funds Weigh In On Cooper Companies

A number of institutional investors have recently added to or reduced their stakes in the business. Alecta Tjanstepension Omsesidigt boosted its position in shares of Cooper Companies by 15.8% during the 3rd quarter. Alecta Tjanstepension Omsesidigt now owns 1,563,000 shares of the medical device company’s stock valued at $107,112,000 after acquiring an additional 213,500 shares during the last quarter. Allworth Financial LP increased its position in shares of Cooper Companies by 23.9% in the third quarter. Allworth Financial LP now owns 1,188 shares of the medical device company’s stock worth $81,000 after purchasing an additional 229 shares during the last quarter. IFP Advisors Inc raised its stake in Cooper Companies by 2,647.8% in the third quarter. IFP Advisors Inc now owns 632 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 609 shares in the last quarter. Swiss Life Asset Management Ltd lifted its position in Cooper Companies by 63.9% during the third quarter. Swiss Life Asset Management Ltd now owns 49,409 shares of the medical device company’s stock valued at $3,387,000 after purchasing an additional 19,264 shares during the last quarter. Finally, CIBC Bancorp USA Inc. bought a new stake in Cooper Companies during the third quarter valued at approximately $1,887,000. 24.39% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $100.00 target price (up previously from $94.00) on shares of Cooper Companies in a research report on Friday, December 5th. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a research note on Friday, December 5th. Wells Fargo & Company increased their price objective on Cooper Companies from $72.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, December 5th. Morgan Stanley raised their target price on Cooper Companies from $76.00 to $83.00 and gave the stock an “equal weight” rating in a research note on Monday, December 8th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Cooper Companies in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $90.15.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.